Abivax: ABTECT study enrollment on track
Abivax today provided an update on the enrollment status into its ABTECT phase III study, disclosing the enrollment of the 600th patient and confirms enrollment completion for Q1 2025 (read-out for Q2 2025).Good to know, Abivax confirmed that to date, baseline participants baseline characteristics
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.